临床HER2阴性晚期乳腺癌中低水平HER2表达的预后影响
PRAEGNANT前瞻性晚期乳腺癌注册研究纳入常规HER2阴性患者,比较HER2 IHC 0与低表达(IHC 1+或IHC 2+/ISH阴性)的临床结局。三阴性患者中低表达不影响无进展生存,IHC 2+总生存在未校正分析中较差但校正后消失;激素受体阳性/HER2阴性患者中低表达对无进展生存和总生存均无影响。结论为常规检测的低水平HER2表达不能区分预后组,但该人群因患病率较高而适合作为HER2靶向临床试验对象。
要点
- 三阴性晚期乳腺癌中低水平HER2表达不影响无进展生存。
- 激素受体阳性/HER2阴性患者中低水平HER2表达对无进展生存和总生存均无预后影响。
- 常规检测的低水平HER2表达不能将患者区分为不同预后组。
核心结论
- 常规临床检测的低水平HER2表达未能将晚期乳腺癌患者区分为不同预后组。
- 低水平HER2表达患者患病率较高,值得作为以HER2为靶点的潜在治疗临床试验对象。
研究设计与样本
- PRAEGNANT为前瞻性晚期乳腺癌注册研究(NCT02338167),聚焦分子生物标志物。
- 分析纳入常规HER2阴性的晚期乳腺癌患者,接受任何类型治疗且处于各治疗线均符合条件。
- 按HER2 IHC 0(无表达)与低表达(IHC 1+或IHC 2+/ISH阴性)分组比较临床结局。
主要发现
- 三阴性晚期乳腺癌患者中,低水平HER2表达不影响无进展生存。
- 三阴性患者未校正分析中,IHC 2+者总生存较无HER2表达者更差(风险比2.24,95%置信区间1.12-4.47),校正分析后该效应未维持。
- 激素受体阳性/HER2阴性患者中,低水平HER2表达对无进展生存和总生存均无影响。
临床怎么用
- 常规IHC/ISH检测的低水平HER2表达不宜单独用于晚期乳腺癌预后分层。
- 低水平HER2表达患者可考虑纳入以HER2为靶点的临床试验。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Assessment of HER2 overexpression using immunohistochemistry (IHC) and/or in situ hybridisation (ISH) for the detection of HER2 amplifications is standard to identify patients for established HER2-directed treatments. Patients with lower HER2 expression levels have recently also become candidates for novel therapies targeting HER2. This study aimed to assess tumour and patient characteristics and prognosis in patients with advanced breast cancer (aBC), relative to low HER2 expression levels. METHODS: PRAEGNANT is a prospective aBC registry (NCT02338167), focusing on molecular biomarkers. Patients in all therapy lines receiving any kind of treatment are eligible. This analysis includes patients with conventionally HER2-negative aBC. Clinical outcome was compared in the groups with no (IHC score 0) or with low HER2 expression (IHC 1+, or IHC 2+/ISH negative). RESULTS: Low HER2 expression levels in triple-negative aBC patients did not influence progression-free survival. Overall survival appeared poorer in patients with IHC 2+ compared with patients with no HER2 expression in the unadjusted analysis (hazard ratio 2.24, 95% confidence interval 0.1.12-4.47). However, this effect was not maintained in the adjusted analysis. In HER2-negative, hormone receptor-positive patients, low HER2 expression appeared to have no effect on prognosis, neither progression-free survival nor overall survival. CONCLUSIONS: We could not demonstrate that HER2 expression at a low level and assessed in clinical routine can differentiate patients into prognostic groups. However, the prevalence of patients with a low expression makes this population interesting for clinical trials with potentially active treatments using HER2 as a target.
引用
- Hein A, Hartkopf AD, Emons J, et al. Prognostic effect of low-level HER2 expression in patients with clinically negative HER2 status. Eur J Cancer. 2021. PMID: 34311211. doi:10.1016/j.ejca.2021.06.033
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。